Luteal Phase Support During Frozen Embryo Transfer Cycle

• Status: Completed
• Trial end date: 2019-04-30
• Target enrollment: 0
• Participant gender: Female

Summary

We aimed to decrease quantity of exogenous estrogen and evaluated the success rate of ongoing pregnancy in women undergone artificial FET who have a surplus embryos at previous fertility treatment cycles.

In this study, endometrial prepared with standard long GnRH protocol and for luteal phase support patients received 6 mg oral E2 and intramuscularly P 100 mg/d and embryos on day 2-3 were transferred. Control group continued E2 until 12 week of pregnancy, while for cases after identify gestational sac with heart beat (the 6 week of pregnancy) by vaginal ultrasonography, E2 will discontinued.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Royan Institute
• Treatments: Estradiol; Estradiol 17 beta-cypionate; Estradiol 3-benzoate; Estrogens; Polyestradiol phosphate; Progesterone; Saw palmetto extract

Criteria

Inclusion Criteria:

1. Patients with surplus embryos undergone infertility treatment cycles (e.g. OHSS, inadequate endometrium, surplus frozen embryo from any cause)

2. Age 21-37 years

3. Normal BMI (18.54. IVF / ICSI or IVF or ICSI cycles with antagonists or agonists protocols

5. Frozen embryos on 2-3 days

Exclusion Criteria:

1. Endometrial thickness ≤7mm

2. Egg Donors

3. Surrogacy

4. Male factor infertility with azoospermia

5. Age <37 years old

6. Hydrosalpinx

7. Uterine anomalies

8. Myoma with a compression effect or submocusa myoma

9. PGD

10. Blastocyst embryo transfer, ZIFT and GIFT